-
公开(公告)号:US11419821B2
公开(公告)日:2022-08-23
申请号:US16103192
申请日:2018-08-14
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil
IPC: A61K38/54 , A61K38/48 , A61K9/16 , A61K9/50 , A23L33/17 , A61K38/46 , A61K38/47 , A61J15/00 , A61K9/00 , A61K9/107
Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
-
2.
公开(公告)号:US20150150955A1
公开(公告)日:2015-06-04
申请号:US14612580
申请日:2015-02-03
Applicant: Curemark LLC
Inventor: Joan M. Fallon , Matthew Heil
CPC classification number: A61K9/1682 , A23L33/17 , A23V2002/00 , A61J15/00 , A61K9/0053 , A61K9/009 , A61K9/1075 , A61K9/16 , A61K9/1617 , A61K9/167 , A61K9/5015 , A61K9/5063 , A61K38/465 , A61K38/47 , A61K38/48 , A61K38/4826 , A61K38/54 , C12Y301/01003 , C12Y302/01 , C12Y304/21001 , Y02A50/473 , Y02A50/481 , A61K2300/00
Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
Abstract translation: 本发明涉及包衣消化酶制剂和酶递送系统以及包含该制剂的药物组合物。 本发明还涉及用于治疗ADD,ADHD,自闭症,囊性纤维化和其他行为和神经障碍的人的系统,药物组合物和制剂的制备和使用方法。
-
公开(公告)号:US20240156924A1
公开(公告)日:2024-05-16
申请号:US18327740
申请日:2023-06-01
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
CPC classification number: A61K38/54 , A61K9/0053 , A61K38/465 , A61K38/47 , A61K38/48 , A61K45/06 , A61P25/00 , C12Y301/01 , C12Y302/01 , C12Y304/00
Abstract: Described herein are compositions which include digestive enzymes which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally- or recombinantly-derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
公开(公告)号:US20210145947A1
公开(公告)日:2021-05-20
申请号:US17159846
申请日:2021-01-27
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
Abstract: Described herein are compositions which include digestive enzymes which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally- or recombinantly-derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
公开(公告)号:US09687452B2
公开(公告)日:2017-06-27
申请号:US14693711
申请日:2015-04-22
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil
IPC: A61K9/16 , A61K38/48 , A61K38/54 , A61K9/50 , A61K38/46 , A61K38/47 , A61J15/00 , A61K9/00 , A61K9/107 , A23L33/17
CPC classification number: A61K9/1682 , A23L33/17 , A23V2002/00 , A61J15/00 , A61K9/0053 , A61K9/009 , A61K9/1075 , A61K9/16 , A61K9/1617 , A61K9/167 , A61K9/5015 , A61K9/5063 , A61K38/465 , A61K38/47 , A61K38/48 , A61K38/4826 , A61K38/54 , C12Y301/01003 , C12Y302/01 , C12Y304/21001 , Y02A50/473 , Y02A50/481 , A61K2300/00
Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
-
公开(公告)号:US11541009B2
公开(公告)日:2023-01-03
申请号:US17410743
申请日:2021-08-24
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil , James J. Fallon , Janice Hughes
Abstract: Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
-
公开(公告)号:US10940187B2
公开(公告)日:2021-03-09
申请号:US16281908
申请日:2019-02-21
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
Abstract: Disclosed in this application are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder. Also disclosed is a method for treating an individual with Schizophrenia or a Schizophreniform Disorder using digestive enzymes and their derivatives to alleviate the symptoms of Schizophrenia or a Schizophreniform Disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder.
-
公开(公告)号:US10716835B2
公开(公告)日:2020-07-21
申请号:US15265620
申请日:2016-09-14
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil , James Fallon , James Szigethy
Abstract: This disclosure relates to the prevention and treatment of Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes. The disclosure further relates to the use of an individual's fecal chymotrypsin level as an indicator, e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
-
公开(公告)号:US10350278B2
公开(公告)日:2019-07-16
申请号:US13836135
申请日:2013-03-15
Applicant: Curemark, LLC
Inventor: Joan M. Fallon , Matthew Heil , James Szigethy , James J. Fallon
Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.
-
公开(公告)号:US10279016B2
公开(公告)日:2019-05-07
申请号:US15265415
申请日:2016-09-14
Applicant: CUREMARK, LLC
Inventor: Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
-
-
-
-
-
-
-
-